Q-omics provides the consensus-scored TMEM70 profile across patient tissues and cancer cell-line models. TMEM70 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM70 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TMEM70 protein abundance shows 19,773 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where TMEM70 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM70 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM70 survival associations across molecular data types. TMEM70 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM70 RNA expression–survival associations across cancer types. High TMEM70 expression shows unfavorable associations in UVM, KICH, ESCA, LGG, KIRP and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM70 RNA expression.
This table summarizes TMEM70 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM70. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM70 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, COAD, LIHC and BRCA. The KIRC box plot shows higher TMEM70 RNA expression in tumor versus normal tissue (log2 FC = +0.413, t-test p < 0.001).
This table shows molecular features associated with TMEM70 in patient tissues and cancer cell lines. In patient samples, TMEM70 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM70 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LIVER.
